// App-Quantinova.ai

: Utility of Serum Cystatin C (SCysC) to Assess AKI and Day 90 (D90) Major Kidney Adverse Events (MAKE90) Following Cardiac Surgery (CS) in Subjects Treated with QPI-1002

Researchers

Presenter

  • LukasJ.Lehner

Principal Investigators

  • U.Schwertschlag

  • MatthiasThielmann

  • AndreLamy

  • DavidCorteville

  • D.P.Cafaro

  • A.Patel

  • MadhavSwaminathan

  • D.J.Odenheimer

  • P.Chan

  • GaborSzabo

  • YuvalMathews

  • D.Rothenstein

  • ElizabethC.Squiers

Medical Centers

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Quark Pharmaceuticals, Inc, Fremont, California, United States

  • West-German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany

  • McMaster University, Hamilton, ON, Canada

  • McLaren Northern Michigan, Petoskey, United States

  • Duke University, Durham, North Carolina, United States

  • University Clinic Heidelberg, Heidelberg, Germany

  • Quark Pharmaceuticals, Nes Ziona, Israel

Locations

  • Germany

  • United States

  • Canada

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Cystatin C

Drug/Treatment

  • QPI 1002

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved